Evaluation of Subcutaneous Immunotherapy Towards Pollen in Children

• Status: Active, not recruiting
• Trial end date: 2022-01-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective is to prospectively explore associations between immunological parameters in blood and clinical effect of subcutaneous immunotherapy (SCIT) in children with severe allergy towards pollen. Half of the children will receive SCIT while the other half will start SCIT after the study is finished. Clinical evaluations of symptoms and an immunological survey will be performed before start of SCIT and after one year of treatment. Some of the immunological parameters will also be checked after 6 months of treatment

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Karolinska Institutet
• Treatments: Immunologic Factors

Criteria

Inclusion Criteria:

• Seasonal Rhinoconjunctivitis caused by grass and/or birch pollen allergy

• Insufficient clinical effect of symptomatic treatment (antihistamine, nasal corticosteroids)

• IgE antibodies to grass and/or birch pollen antigens

Exclusion Criteria:

• severe comorbidity, severe asthma, pregnancy